Immunovant Inc

IMVT11 Dec 2024
Healthcare
$28.88
+0.01 (+0.77%)
Lowest Today
$28.48
Highest Today
$29.3
Today’s Open
$28.88
Prev. Close
$28.7
52 Week High
$45.58
52 Week Low
$24.61
To Invest in Immunovant Inc

Immunovant Inc

Healthcare
IMVT11 Dec 2024
+0.01 (+0.77%)
1M
3M
6M
1Y
5Y
Low
$28.48
Day’s Range
High
$29.3
28.48
52 Week Low
$24.61
52-Week Range
52 Week High
$45.58
24.61
1 Day
-
1 Week
+1.62%
1 month return
-7.95%
3 month return
-3.3%
6 month return
+12.81%
1 Year return
-27.92%
3 Years return
+273.21%
5 Years return
+178.64%
10 Years return
-
Institutional Holdings
FMR Inc
8.54
Vanguard Group Inc
4.54
BlackRock Inc
3.35
Fidelity Growth Compy Commingled Pl S
3.22
Deep Track Capital, LP
2.96
Armistice Capital, LLC
2.42
Fidelity Growth Company Fund
2.34

Market Status

Fundamentals
Market Cap
4200.99 mln
PB Ratio
9.36
PE Ratio
0
Enterprise Value
3728.08 mln
Total Assets
666.36 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Organisation
Immunovant Inc
Employees
207
Industry
Biotechnology
CEO
Dr. Peter  Salzmann M.B.A., M.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities